Why the study?
Epistaxis is common with antithrombotic therapy and troublesome to patients, but its frequency, severity, and outcomes are poorly characterized.
Does edoxaban reduce the risk of epistaxis compared to warfarin in anticoagulated patients with atrial fibrillation?
Does edoxaban reduce the risk of epistaxis compared to warfarin in anticoagulated patients with atrial fibrillation?
In patients with atrial fibrillation, a lower-dose edoxaban regimen reduces the risk of epistaxis by 27% compared to warfarin, while a higher-dose regimen has a similar risk.
Answers are grounded in this paper and cite their sources.
Informs edoxaban dose selection to reduce epistaxis in AF; extends dose-specific bleeding safety data from prior RCTs.
BACKGROUND: Epistaxis is common with antithrombotic therapy and is often troublesome to patients, yet its frequency, severity, and outcomes are poorly characterized. METHODS AND Compared with warfarin, higher-dose edoxaban regimen had similar risk of epistaxis (hazard ratio [HR], 1.09 [95% CI, 0.95-1.26]), whereas lower-dose edoxaban regimen conferred reduced risk (HR, 0.73 [95% CI, 0.62-0.86]). CONCLUSIONS: Epistaxis was frequent, and despite being overall less severe than nonepistaxis bleeding, was associated with similar rates of anticoagulant discontinuation. Compared with warfarin, lower-dose edoxaban regimen reduced the risk of epistaxis by 27% whereas higher-dose edoxaban regimen had no effect. REGISTRATION: URL: https://clinicaltrials.gov; Unique Identifier: NCT00781391.
No takes yet. Share an insight, caveat, or question.
Semco et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: